6-bromo-1,2,3,4-tetrahydro-β-carboline | 23046-69-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-bromo-1,2,3,4-tetrahydro-β-carboline
• 英文别名: 6-bromotryptoline；6-Bromo-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
• CAS: 23046-69-7
• 化学式: C₁₁H₁₁BrN₂
• 分子量: 251.126
• InChiKey: WUTVTUWSFMYRJK-UHFFFAOYSA-N

物化性质

• 熔点：
  234-237 °C(Solv: methanol (67-56-1))
• 沸点：
  404.7±40.0 °C(Predicted)
• 密度：
  1.560±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-bromo-1,2,3,4-tetrahydro-β-carboline 在 sodium tungstate 、 双氧水 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以17%的产率得到6-bromo-3,4-dihydro-β-carboline 2-oxide
  参考文献：
  名称：

  Still, Ian W. J.; Strautmanis, Juris R., Canadian Journal of Chemistry, 1990, vol. 68, # 8, p. 1408 - 1419

  摘要：

  DOI：
• 作为产物：
  描述：

  6-bromo-2,3,4,9-tetrahydro-β-carbolin-1-one 在 lithium aluminium tetrahydride 作用下， 以 1,4-二氧六环 为溶剂， 生成 6-bromo-1,2,3,4-tetrahydro-β-carboline
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel Tetrahydro-β-carboline Derivatives as Antitumor Growth and Metastasis Agents through Inhibiting the Transforming Growth Factor-β Signaling Pathway

  摘要：

  The transforming growth factor beta (TGF beta) signaling cascade is considered as one of the pivotal oncogenic pathways in most advanced cancers. Inhibition of the TGF beta signaling pathway by specific antagonists, neutralizing antibodies, or small molecules is considered as an effective strategy for the treatment of tumor growth and metastasis. Here we demonstrated the identification of a series of tetrahydro-beta-carboline derivatives from virtual screening which potentially inhibit the TGF beta signaling pathway. Optimization of the initial hit compound 2-benzoyl-1,3,4,9-tetrahydro-beta-carboline (8a) through substitution at different positions to define the structure-activity relationship resulted in the discovery of potent inhibitors of the TGF beta signaling pathway. Among them, compound 8d, one of the tested compounds, not only showed potent inhibition of lung cancer cell proliferation and migration in vitro but also strongly suppressed growth of lung cancer and breast cancer in vivo.

  DOI：

  10.1021/jm401117t

文献信息

• [EN] (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS<br/>[FR] PYRIDOINDOLES (1-AZINONE)-SUBSTITUÉS EN TANT QU'ANTAGONISTES MCH
  申请人：ALBANY MOLECULAR RES INC

  公开号：WO2009089482A1

  公开（公告）日：2009-07-16

  Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, -O-alkyl, -S-alkyl, alkyl, halo, -CF3, and -CN; G is -CR12R13-NR5- or -NR5-CR12R13; R5 is H, optionally substituted alkyl, optionally substituted heterocycle, -C(=O)-R6, -C(=O)-O-R7, or -C(=O)-NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is -CH2-O-, -CH2CH2-, -CH=CH- or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.

  将吡啶吲哚替代物用于制药组合物中，用于治疗各种疾病，对应于式（I），其中R1为H或可选择的取代烷基；R2、R3、R4分别独立选择自H、-O-烷基、-S-烷基、烷基、卤素、-CF3和-CN；G为-CR12R13-NR5-或-NR5-CR12R13；R5为H、可选择的取代烷基、可选择的取代杂环、-C(=O)-R6、-C(=O)-O-R7或-C(=O)-NR19R20；R6和R7分别为可选择的取代烷基或可选择的取代杂环；R8、R9、R10、R11、R12、R13、R19和R20分别独立选择自H或可选择的取代烷基；R14和R15分别独立为H或卤素；L为-CH2-O-、-CH2CH2-、-CH=CH-或一个键；B为芳基或杂芳基或环烷基；但条件是，当L为直接键时，B不能是未取代的杂芳基或单取代氟的杂芳基。
• [EN] CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS<br/>[FR] DERIVES DE CARBOLINE ET DE BETACARBOLINE INHIBITEURS DE L'ENZYME HDAC
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2004113336A1

  公开（公告）日：2004-12-29

  Compounds of formula (IA) and (IB) are inhibitors of histone deacetylase activity and useful for the treatment of, inter alia, cancers: wherein fused rings A1 and A2 are optionally substituted; linker radical R1 represents a radical of formula

  式（IA）和（IB）的化合物是组蛋白去乙酰化酶活性的抑制剂，用于治疗癌症等疾病：其中融合的环A1和A2可以选择性地被取代；连接基团R1代表一个公式的基团。
• IBX-mediated oxidative addition of isocyanides to cyclic secondary amines: total syntheses of alangiobussine and alangiobussinine
  作者：Mayur D. Ambule、Shashank Tripathi、Anirban Ghoshal、Ajay K. Srivastava

  DOI：10.1039/c9cc05215a

  日期：——

  activate imine facilitating isocyanide addition. Detailed mechanistic investigations were performed by isotopic labeling and real-time NMR experiments. The method was utilized for the gram scale syntheses of two alkaloids alangiobussine and alangiobussinine in 63% and 45% overall yield, respectively.

  本研究描述了一种通过IBX介导的异氰酸酯向色氨酸和1,2,3,4-四氢异喹啉的氧化加成反应合成C（1）-羧酰胺的稳健而通用的方法。在这种转化中，IBX扮演氧化剂和路易斯酸的双重角色，以激活亚胺促进异氰酸酯的添加。通过同位素标记和实时NMR实验进行了详细的机理研究。该方法被用于两种生物碱类langobussine和langobussinine的克级合成，总收率分别为63％和45％。
• Late-Stage Diversification of Biologically Active Molecules via Chemoenzymatic C–H Functionalization
  作者：Landon J. Durak、James T. Payne、Jared C. Lewis

  DOI：10.1021/acscatal.5b02558

  日期：2016.3.4

  halogenase were used to selectively halogenate a number of biologically active aromatic compounds. Subsequent Pd-catalyzed cross-coupling reactions on the crude extracts of these reactions were used to install aryl, amine, and ether substituents at the halogenation site. This simple, chemoenzymatic method enables nondirected functionalization of C–H bonds on a range of substrates to provide access to

  瑞贝卡霉素卤化酶的工程变体用于选择性卤化许多具有生物活性的芳香族化合物。随后对这些反应的粗提取物进行钯催化的交叉偶联反应，用于在卤化位点安装芳基、胺和醚取代基。这种简单的化学酶方法能够对一系列底物上的 C-H 键进行非定向功能化，从而提供通过其他方法制备具有挑战性或效率低下的衍生物。
• (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES
  申请人：GUZZO Peter Robert

  公开号：US20090275590A1

  公开（公告）日：2009-11-05

  Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R 1 is H or optionally substituted alkyl; R 2 , R 3 , R 4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF 3 , and —CN; G is —CR 12 R 13 —NR 5 — or —NR 5 —CR 12 R 13 ; R 5 ; is H, optionally substituted alkyl, optionally substituted heterocycle, —C(═O)—R 6 , —C(═O)—O—R 7 , or —C(═O)—NR 19 R 20 ; R 6 and R 7 are each optionally substituted alkyl or optionally substituted heterocycle; R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 19 and R 20 are each independently selected from H or optionally substituted alkyl; R 14 and R 15 are each independently H or halogen; L is —CH 2 —O—, —CH 2 CH 2 —, —CH═CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.

  替代吡啶并吡唑类化合物可用于制备用于治疗各种疾病的药物组合物，其对应于式（I），其中R1是H或可选择的取代烷基; R2，R3，R4分别选自H，—O-烷基，—S-烷基，烷基，卤素，—CF3和—CN; G是—CR12R13—NR5—或—NR5—CR12R13; R5;是H，可选择的取代烷基，可选择的取代杂环，—C（═O）—R6，—C（═O）—O—R7或—C（═O）—NR19R20; R6和R7分别是可选择的取代烷基或可选择的取代杂环; R8，R9，R10，R11，R12，R13，R19和R20分别选自H或可选择的取代烷基; R14和R15分别是H或卤素; L是—CH2—O—，—CH2CH2—，—CH═CH—或键; B是芳基或杂芳基或环烷基; 前提是，当L是直接键时，B不能是未取代的杂芳基或单取代氟的杂芳基。